Figure 8

Investigation of MFO-BTO-DOX nanoformulation on 4T1 tumors in vivo. (a) scheme of study groups (control, MENs, MENs+DOX−, and MENs+DOX+ for 45 min); (b) tumor growth rates; (c) mice weight, (*) indicate significant differences compared to the control; (e) FLIR thermographs of MENs-DOX-injected mice before and immediately after MF exposure indicate no temperature increase due to low-frequency, low-intensity MF treatment (d) confirming absence of hyperthermia.